iCAD

Description

iCAD is dedicated to creating a world where cancer cannot hide, developing advanced artificial intelligence solutions for early cancer detection. Their core offering, the ProFound Breast Health Suite, is designed to empower both healthcare providers and patients. This suite comprises three key components: Detection, Density, and Risk assessment.

The ProFound AI Detection solution revolutionizes mammography screenings by identifying cancers earlier and with greater accuracy and efficiency. It supports both 2D and 3D mammography and is available globally. By integrating this AI into their workflow, radiologists can reduce reading time, minimize recalls, and improve overall patient care.

Complementing detection, the ProFound AI Density assessment provides objective, reliable, and consistent scoring of breast density. Understanding breast density is crucial as it can significantly elevate breast cancer risk. This feature simplifies and standardizes density assessments, providing clinicians with dependable results that can inform personalized treatment plans.

The ProFound AI Risk evaluation introduces the world's first image-based risk model, which is reported to be 2.4 times more accurate than traditional methods. This capability helps identify women at high risk of developing cancer before or at their next screening, enabling proactive measures and earlier detection of interval cancers. It's important to note that ProFound AI Risk is CE Marked and Health Canada Licensed, and available in the US for investigational use.

iCAD's platform is built for seamless integration into existing workflows, offering flexible and secure deployment options for smooth IT adoption. The company emphasizes its commitment to clinical evidence and proven patient outcomes, backed by extensive experience and a large dataset of trained algorithms. They have been instrumental in reading millions of mammograms worldwide, contributing significantly to advancements in breast cancer screening technology.

iCAD's Core Features

• AI-powered cancer detection for mammography

• Breast density assessment with objective scoring

• Image-based breast cancer risk evaluation

• Supports 2D and 3D mammography

• Reduces radiologist reading time

• Aims to improve cancer detection accuracy

• Designed for seamless workflow integration

• Flexible and secure deployment options

• Clinically proven AI solutions

• Available globally in various countries

• Investigational use in the US for risk assessment

How to use iCAD?

1. 1

   Integrate: Implement ProFound AI solutions into your existing mammography workflow.

2. 2

   Configure: Set up deployment options for flexible and secure IT adoption.

3. 3

   Detect: Utilize AI-powered detection for earlier and more accurate cancer identification.

4. 4

   Assess Density: Employ objective density scoring to inform personalized treatment plans.

5. 5

   Evaluate Risk: Use image-based risk models to identify high-risk patients.

6. 6

   Optimize: Enhance reading efficiency and improve patient outcomes.

iCAD's Use Cases

• Early Cancer Detection
• Mammography Workflow Enhancement
• Breast Density Assessment
• High-Risk Patient Identification
• Interval Cancer Reduction
• Personalized Treatment Planning

FAQ from iCAD

• What is iCAD's primary focus in cancer detection?

  iCAD's primary focus is on developing AI-powered solutions for early cancer detection, particularly in breast health, aiming to make cancer less likely to hide.

• What are the components of the ProFound Breast Health Suite?

  The ProFound Breast Health Suite includes AI solutions for Cancer Detection, Density Assessment, and Risk Evaluation.

• How does iCAD's AI help radiologists?

  iCAD's AI helps radiologists by improving cancer detection accuracy, reducing reading time, minimizing recalls, and enhancing workflow efficiency.

• Can iCAD's solutions detect cancer in women with dense breast tissue?

  Yes, iCAD's solutions are designed to improve cancer detection, and their Density Assessment feature specifically addresses the challenges of dense breast tissue.

• What is the accuracy of iCAD's image-based risk model?

  iCAD's image-based risk model is reported to be 2.4 times more accurate than traditional risk assessment models.

• Is iCAD's ProFound AI Risk available in the US?

  ProFound AI Risk is CE Marked and Health Canada Licensed, and is available in the US for investigational use.

• What types of mammography does iCAD's detection solution support?

  iCAD's detection solution supports both 2D and 3D mammography.

• How does iCAD ensure seamless integration?

  iCAD offers flexible and secure deployment options and aims for seamless integration within existing workflows and trusted systems.

• What is the main benefit of early cancer detection?

  Early cancer detection significantly improves the 5-year relative survival rate, which is 99% for breast cancer when detected early.

• Where are iCAD's solutions available?

  iCAD's solutions are available in the US and globally in various countries.